Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Hwa-ping Feng

Showing results (11-20 of 37) with videos related to

Pageof 4
Sort By:
Antimicrobial Agents and Chemotherapy|September 29, 2020
Outcomes in Participants with Renal Impairment from a Phase 3 Clinical Trial for Ceftolozane/Tazobactam Treatment of Nosocomial Pneumonia (ASPECT-NP)Jennifer A Huntington, Brian Yu, Linping Li, et al.
Journal of Clinical Pharmacology|September 1, 2022
Probability of Target Attainment Analyses to Inform Ceftolozane/Tazobactam Dosing Regimens for Patients With Hospital-Acquired or Ventilator-Associated Bacterial Pneumonia and End-Stage Renal Disease Receiving Intermittent HemodialysisHwa-Ping Feng, Yogesh T Patel, Zufei Zhang, et al.
Journal of Clinical Pharmacology|January 13, 2018
Pharmacokinetic Interactions Between Elbasvir/Grazoprevir and Immunosuppressant Drugs in Healthy VolunteersHwa-Ping Feng, Luzelena Caro, Christine M Fandozzi, et al.
Respiratory Medicine|December 15, 2022
Effects of an inhaled soluble guanylate cyclase (sGC) stimulator MK-5475 in pulmonary arterial hypertension (PAH)Ednan K Bajwa, Dawn Cislak, John Palcza, et al.
Journal of Clinical Pharmacology|October 6, 2022
Ceftolozane/Tazobactam Probability of Target Attainment in Patients With Hospital-Acquired or Ventilator-Associated Bacterial PneumoniaWei Gao, Yogesh T Patel, Zufei Zhang, et al.
European Journal of Clinical Pharmacology|February 11, 2015
Pharmacokinetic interaction between HCV protease inhibitor boceprevir and methadone or buprenorphine in subjects on stable maintenance therapyEllen G J Hulskotte, R Douglas Bruce, Hwa-Ping Feng, et al.
Hepatology Communications|February 7, 2018
Concomitant proton pump inhibitor use does not reduce the efficacy of elbasvir/grazoprevir: A pooled analysis of 1,322 patients with hepatitis C infectionNancy Reau, Michael N Robertson, Hwa-Ping Feng, et al.
International Journal of Antimicrobial Agents|January 14, 2023
A single- and multiple-dose study to characterize the pharmacokinetics, safety, and tolerability of ceftolozane/tazobactam in healthy Chinese participantsNa Liu, Xiaohong Wang, Jixiang Zhu, et al.
Antimicrobial Agents and Chemotherapy|April 26, 2022
Exposure-Efficacy Analyses Support Optimal Dosing Regimens of Ceftolozane/Tazobactam in Participants with Hospital-Acquired/Ventilator-Associated Bacterial Pneumonia in ASPECT-NPWei Gao, Julie Passarell, Yogesh T Patel, et al.
European Journal of Clinical Pharmacology|January 26, 2019
Pharmacokinetics of elbasvir and grazoprevir in subjects with end-stage renal disease or severe renal impairmentLuzelena Caro, Larissa Wenning, Hwa-Ping Feng, et al.
Pageof 4

Showing results (11-20 of 37) with videos related to

Sort By:
Pageof 4
Antimicrobial Agents and Chemotherapy|September 29, 2020
Outcomes in Participants with Renal Impairment from a Phase 3 Clinical Trial for Ceftolozane/Tazobactam Treatment of Nosocomial Pneumonia (ASPECT-NP)Jennifer A Huntington, Brian Yu, Linping Li, et al.
Journal of Clinical Pharmacology|September 1, 2022
Probability of Target Attainment Analyses to Inform Ceftolozane/Tazobactam Dosing Regimens for Patients With Hospital-Acquired or Ventilator-Associated Bacterial Pneumonia and End-Stage Renal Disease Receiving Intermittent HemodialysisHwa-Ping Feng, Yogesh T Patel, Zufei Zhang, et al.
Journal of Clinical Pharmacology|January 13, 2018
Pharmacokinetic Interactions Between Elbasvir/Grazoprevir and Immunosuppressant Drugs in Healthy VolunteersHwa-Ping Feng, Luzelena Caro, Christine M Fandozzi, et al.
Respiratory Medicine|December 15, 2022
Effects of an inhaled soluble guanylate cyclase (sGC) stimulator MK-5475 in pulmonary arterial hypertension (PAH)Ednan K Bajwa, Dawn Cislak, John Palcza, et al.
Journal of Clinical Pharmacology|October 6, 2022
Ceftolozane/Tazobactam Probability of Target Attainment in Patients With Hospital-Acquired or Ventilator-Associated Bacterial PneumoniaWei Gao, Yogesh T Patel, Zufei Zhang, et al.
European Journal of Clinical Pharmacology|February 11, 2015
Pharmacokinetic interaction between HCV protease inhibitor boceprevir and methadone or buprenorphine in subjects on stable maintenance therapyEllen G J Hulskotte, R Douglas Bruce, Hwa-Ping Feng, et al.
Hepatology Communications|February 7, 2018
Concomitant proton pump inhibitor use does not reduce the efficacy of elbasvir/grazoprevir: A pooled analysis of 1,322 patients with hepatitis C infectionNancy Reau, Michael N Robertson, Hwa-Ping Feng, et al.
International Journal of Antimicrobial Agents|January 14, 2023
A single- and multiple-dose study to characterize the pharmacokinetics, safety, and tolerability of ceftolozane/tazobactam in healthy Chinese participantsNa Liu, Xiaohong Wang, Jixiang Zhu, et al.
Antimicrobial Agents and Chemotherapy|April 26, 2022
Exposure-Efficacy Analyses Support Optimal Dosing Regimens of Ceftolozane/Tazobactam in Participants with Hospital-Acquired/Ventilator-Associated Bacterial Pneumonia in ASPECT-NPWei Gao, Julie Passarell, Yogesh T Patel, et al.
European Journal of Clinical Pharmacology|January 26, 2019
Pharmacokinetics of elbasvir and grazoprevir in subjects with end-stage renal disease or severe renal impairmentLuzelena Caro, Larissa Wenning, Hwa-Ping Feng, et al.
Pageof 4